LoadingLoadingLoadingNo insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
D.E. Shaw
$37.2M
added
Qube Research
$21.6M
added
Sells/Trims (1)
Citadel
$43.4M
trimmed
Sells (2)
No tracked top-trader positions in ALC as of Oct 24, 06:54 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 10, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.76 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$0.85 to $0.96
Revenue expected
15 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 10, 2026 | $0.84 / $0.76Yahoo Finance | +11.21% beat | $2.82B No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $0.85 / $0.82Yahoo Finance | +4.06% beat | $2.65B No estimate | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $0.78 / $0.87Yahoo Finance | -10.34% miss | $2.72B No estimate | Unavailable |
| Sep 30, 2025 | Nov 11, 2025 | $0.79 / $0.85Yahoo Finance | -7.06% miss | $2.61B No estimate | Unavailable |
| Jun 30, 2025 | Aug 19, 2025 | $0.76 / $0.71Alpha Vantage | +7.04% beat | $2.60B No estimate | Unavailable |
| Mar 31, 2025 | May 13, 2025 | Unavailable | - | $2.47B No estimate | Unavailable |
| Dec 31, 2024 | Feb 25, 2025 | $0.72 / $0.72Alpha Vantage | +0.00% in line | $2.50B No estimate | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | $0.81 / $0.74Alpha Vantage | +9.46% beat | $2.45B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.61B | $2.72B | $2.65B | $2.82B |
| Cost of what it sold | $1.16B | $1.25B | $1.16B | $1.15B |
| Gross profit | $1.46B | $1.47B | $1.50B | $1.68B |
| What it spent | ||||
| Research and development | $250.0M | $273.0M | $240.2M | $663.0M |
| Sales and admin | $865.0M | $901.0M | $882.0M | $964.0M |
| Other operating costs | — | -$14.0M | -$37.7M | $37.0M |
| Total operating expenses | $1.13B | $1.16B | $1.08B | $1.66B |
| What was left | ||||
| Operating profit | $332.0M | $313.0M | $410.9M | $11.0M |
| Interest on debt | $51.0M | $53.0M | $51.0M | $53.0M |
| Profit before tax | $283.0M | $264.0M | $235.3M | -$46.0M |
| Tax | $46.0M | $47.0M | $50.0M | -$46.0M |
| Net profit | $237.0M | $217.0M | $185.3M | $0 |
| EBITDA | $664.6M | $740.0M | $564.8M | $800.0M |
This stock is trending upward, and looks overbought after a fast run-up.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
BullishOct 22Alcon Pays $550 Million for Neurotech and Its MacTel Cell Therapy
Leans bullishOct 22Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
BullishOct 22Needham Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $98
BullishOct 22Alcon acquires Neurotech, MacTel therapy Encelto
BullishOct 22Alcon acquires Neurotech for USD 550 million, adding first approved MacTel therapy
Leans bullishOct 21Alcon Inc. stays a Buy with strong FDA approvals, growth, and undervalued stock potential.
BullishOct 21Alcon Price Target Maintained With a $98.00/Share by Needham
Leans bullishOct 21
